Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas.
OBJECTIVE
The glucose-lowering effect of glucagon-like peptide-1 (GLP-1) is based not only upon its potent insulinotropic actions but also on its ability to restrain glucagon secretion. Surprisingly, the closely related glucose-dependent insulinotropic peptide (GIP) stimulates glucagon release. We examined whether the islet hormone somatostatin, which strongly inhibits glucagon secretion, is involved in this divergent behaviour.


METHODS
At 1.5 mmol/l glucose and therefore minimal insulin secretion, the glucagon, insulin and somatostatin responses to 20 mmol/l glucose, GLP-1, GIP and somatostatin were studied in the presence of a high-affinity monoclonal somatostatin antibody and of a highly specific somatostatin receptor subtype 2 (SSTR2) antagonist (PRL-2903) in the isolated perfused rat pancreas.


RESULTS
In control experiments, GLP-1 at 1 and 10 nmol/l reduced glucagon secretion significantly to 59.0 +/- 6.3% (p < 0.004; n = 5; SSTR2 series; each vs pre-infusion level) and to 48.0 +/- 2.6% (p < 0.001; n = 6; somatostatin antibody series) respectively. During somatostatin antibody administration, GLP-1 still inhibited glucagon secretion significantly, but the effect was less pronounced than in control experiments (p < 0.018). Co-infusion of the SSTR2 antagonist completely abolished the GLP-1-induced suppression of glucagon secretion. In contrast, neither the GIP-induced stimulation of glucagon release nor its inhibition by 20 mmol/l glucose was altered by somatostatin antibody or SSTR2 antagonist administration.


CONCLUSIONS
We conclude that GLP-1 is capable of inhibiting glucagon secretion even in the absence of secretory products from the beta cell. It is highly likely that this is mediated via somatostatin interacting with SSTR2 on rat alpha cells. In contrast, GIP and glucose seem to influence the alpha cell independently of somatostatin secretion.
de Heer
J
J
Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200, Copenhagen N, Denmark.
Rasmussen
C
C
Coy
D H
DH
Holst
J J
JJ
D000818:Animals; D000906:Antibodies / Q000276:immunology; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000494:pharmacology; D005934:Glucagon / Q000378:metabolism*; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D010179:Pancreas / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D010477:Perfusion; D051381:Rats; D017208:Rats, Wistar; D017481:Receptors, Somatostatin / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013004:Somatostatin / Q000276:immunology
D000906:Antibodies; D007328:Insulin; D017481:Receptors, Somatostatin; D013004:Somatostatin; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; C093733:somatostatin receptor 2
Diabetes. 1997 May;46(5):785-91
9133545
Regul Pept. 1983 Apr;6(1):63-9
6191365
Horm Metab Res. 2004 Nov-Dec;36(11-12):747-54
15655703
J Clin Endocrinol Metab. 2007 Feb;92(2):673-80
17105845
Diabetes. 2000 Sep;49(9):1500-10
10969834
J Histochem Cytochem. 2004 Mar;52(3):391-400
14966206
J Clin Invest. 1990 Apr;85(4):983-7
1969425
Diabetes. 2005 Jun;54(6):1808-15
15919803
Biochem Biophys Res Commun. 1994 Nov 30;205(1):341-6
7999046
J Physiol. 2003 Jun 15;549(Pt 3):889-901
12692184
J Clin Invest. 1984 Dec;74(6):2296-9
6392344
Am J Physiol. 1992 Dec;263(6 Pt 1):G908-12
1362042
J Clin Endocrinol Metab. 2000 Nov;85(11):4053-9
11095432
Am J Physiol. 1983 Oct;245(4):G519-24
6194694
Br J Pharmacol. 1998 Nov;125(5):1081-7
9846648
Proc Natl Acad Sci U S A. 1979 Nov;76(11):5901-4
118458
Diabetes. 1992 Jan;41(1):93-7
1345782
Cell Metab. 2008 Jun;7(6):545-54
18522835
Endocrinology. 1978 Aug;103(2):610-5
744105
Nat Cell Biol. 2007 Apr;9(4):453-60
17369816
Diabetes. 2004 Dec;53 Suppl 3:S181-9
15561909
Science. 1974 Apr 26;184(4135):482-4
4594711
Diabetologia. 2007 Feb;50(2):370-9
17136393
Am J Anat. 1986 Jan;175(1):49-58
3953470
Lancet. 1973 Dec 8;2(7841):1299-301
4127645
Diabetologia. 1993 Aug;36(8):741-4
8405741
Diabetes. 1996 Feb;45(2):257-61
8549871
Diabetes. 2004 Apr;53(4):1038-45
15047619
J Clin Invest. 1977 Nov;60(5):1216-9
908761
Regul Pept. 1982 Jun;4(1):13-31
6126917
Front Neuroendocrinol. 1999 Jul;20(3):157-98
10433861
Diabetes. 1999 Jan;48(1):77-85
9892225
Acta Endocrinol (Copenh). 1982 Mar;99(3):416-21
6122321
J Med Chem. 1999 Jun 3;42(11):1863-71
10354394
Nat Cell Biol. 2003 Apr;5(4):330-5
12640462
Proc Natl Acad Sci U S A. 1977 May;74(5):2140-3
325567
Pflugers Arch. 1998 Apr;435(5):583-94
9479010
J Clin Invest. 1988 Jul;82(1):350-3
2455737
PLoS Biol. 2007 Jun;5(6):e143
17503968
Diabetes. 2007 Feb;56(2):438-43
17259389
J Clin Invest. 1991 Feb;87(2):415-23
1991827
Endocr Rev. 1995 Jun;16(3):390-410
7671853
Pancreas. 2001 Oct;23(3):302-8
11590327
Diabetes. 2003 May;52(5):1176-81
12716749
Metabolism. 1990 Sep;39(9 Suppl 2):55-60
1976222
Am J Physiol. 1995 Sep;269(3 Pt 1):E469-77
7573424
Endocrinology. 2000 Jan;141(1):111-7
10614629
Diabetologia. 2003 Jun;46(6):798-801
12764578